T1	Drug 11 24	beta blockers
T2	Temporal 25 57	within 2 months of randomization
T3	Reference_point 44 57	randomization
R1	Has_index Arg1:T2 Arg2:T3	
R2	Has_temporal Arg1:T1 Arg2:T2	
T4	Observation 77 103	listed for transplantation
T5	Procedure 88 103	transplantation
R3	multi Arg1:T4 Arg2:T5	
T6	Temporal 104 135	at time of entry into the study
T7	Reference_point 115 135	entry into the study
R4	Has_index Arg1:T6 Arg2:T7	
R5	Has_temporal Arg1:T4 Arg2:T6	
T8	Mood 139 161	anticipated to undergo
T9	Procedure 162 183	heart transplantation
T10	Procedure 185 215	interventional catheterization
T11	Procedure 220 246	corrective cardiac surgery
T12	Temporal 247 297	during the 7 months following entry into the study
T13	Reference_point 277 297	entry into the study
R6	Has_index Arg1:T12 Arg2:T13	
*	OR T9 T10 T11
T14	Scope 162 246	heart transplantation, interventional catheterization, or corrective cardiac surgery
R7	Has_mood Arg1:T14 Arg2:T8	
R8	Has_temporal Arg1:T14 Arg2:T12	
*	OR T4 T14
T15	Qualifier 312 323	symptomatic
T16	Qualifier 299 308	Sustained
T17	Condition 324 348	ventricular dysrhythmias
T18	Qualifier 349 377	uncontrolled by drug therapy
T19	Procedure 365 377	drug therapy
T20	Drug 365 369	drug
R9	multi Arg1:T19 Arg2:T20	
R10	multi Arg1:T18 Arg2:T19	
*	OR T16 T15
T21	Scope 299 323	Sustained or symptomatic
R11	Has_scope Arg1:T17 Arg2:T21	
T22	Device 395 420	implantable defibrillator
T23	Qualifier 349 364;381 420	uncontrolled by the use of an implantable defibrillator
R12	multi Arg1:T23 Arg2:T22	
*	OR T23 T18
T24	Scope 349 420	uncontrolled by drug therapy or the use of an implantable defibrillator
R13	Has_scope Arg1:T17 Arg2:T24	
T25	Qualifier 429 440	significant
T26	Condition 441 467	cardiac conduction defects
R14	Has_qualifier Arg1:T26 Arg2:T25	
T27	Condition 475 485;500 508	2nd degree AV block
T28	Condition 489 508	3rd degree AV block
*	OR T28 T27 T29
T29	Condition 513 532	sick sinus syndrome
T30	Scope 429 467	significant cardiac conduction defects
T31	Scope 475 532	2nd degree or 3rd degree AV block, or sick sinus syndrome
T32	Negation 534 540	unless
T33	Qualifier 543 554	functioning
T34	Device 555 564	pacemaker
R15	Has_qualifier Arg1:T34 Arg2:T33	
R16	Has_negation Arg1:T34 Arg2:T32	
R17	AND Arg1:T31 Arg2:T34	
R18	Has_scope Arg1:T30 Arg2:T31	
*	OR T17 T30
T35	Qualifier 578 589	Uncorrected
T36	Condition 590 601;624 637	obstructive valve disease
T37	Qualifier 605 611	severe
T38	Condition 612 637	regurgitant valve disease
R19	Has_qualifier Arg1:T36 Arg2:T35	
R20	Has_qualifier Arg1:T38 Arg2:T37	
T39	Condition 639 664	nondilated cardiomyopathy
T40	Qualifier 669 680	significant
T41	Condition 681 721	systemic ventricular outflow obstruction
R21	Has_qualifier Arg1:T41 Arg2:T40	
*	OR T39 T41 T38 T36
T42	Condition 729 754	renovascular hypertension
T43	Condition 770 792	pulmonary hypertension
T44	Mood 758 769	evidence of
R22	Has_mood Arg1:T43 Arg2:T44	
T45	Measurement 794 823	pulmonary vascular resistance
T46	Value 824 838	> 6 Wood units
R23	Has_value Arg1:T45 Arg2:T46	
T47	Scope 794 838	pulmonary vascular resistance > 6 Wood units
T48	Scope 758 792	evidence of pulmonary hypertension
R24	Subsumes Arg1:T48 Arg2:T47	
*	OR T42 T48
T49	Qualifier 840 874	unresponsive to vasodilator agents
T50	Drug 856 874	vasodilator agents
R25	multi Arg1:T49 Arg2:T50	
T51	Drug 883 889	oxygen
T52	Drug 891 904	nitroprusside
T53	Drug 909 921	nitric oxide
*	OR T52 T53 T51
T54	Scope 883 921	oxygen, nitroprusside, or nitric oxide
R26	Subsumes Arg1:T50 Arg2:T54	
T55	Scope 729 839	renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units)
R27	Has_qualifier Arg1:T55 Arg2:T49	
T56	Observation 923 930	History
T57	Temporal 934 941	current
T58	Mood 942 962	clinical evidence of
*	OR T56 T57
T59	Qualifier 963 981	moderate-to-severe
T60	Qualifier 982 987	fixed
T61	Condition 988 1017	obstructive pulmonary disease
T62	Qualifier 1021 1027	severe
T63	Condition 1028 1052	reactive airway diseases
R28	Has_qualifier Arg1:T61 Arg2:T60	
R29	Has_qualifier Arg1:T61 Arg2:T59	
T64	Condition 1060 1066	asthma
R30	Subsumes Arg1:T63 Arg2:T64	
T65	Scope 1028 1067	reactive airway diseases (e.g., asthma)
R31	Has_qualifier Arg1:T65 Arg2:T62	
*	OR T61 T65
T66	Scope 963 1067	moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma)
R32	Has_mood Arg1:T66 Arg2:T58	
T67	Scope 923 941	History or current
R33	Has_scope Arg1:T66 Arg2:T67	
T68	Procedure 1078 1093	hospitalization
T69	Mood 1068 1077	requiring
R34	Has_mood Arg1:T68 Arg2:T69	
T70	Temporal 1094 1117	within the past 2 years
T71	Temporal 1129 1138	currently
T72	Drug 1145 1178	long-term inhaled bronchodilators
R35	Has_temporal Arg1:T72 Arg2:T71	
R36	Has_temporal Arg1:T68 Arg2:T70	
T73	Reference_point 1101 1117	the past 2 years
R37	Has_index Arg1:T70 Arg2:T73	
*	OR T68 T72
T74	Scope 1068 1178	requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators
R38	Has_scope Arg1:T66 Arg2:T74	
T75	Qualifier 1180 1185	Renal
T76	Qualifier 1187 1194	hepatic
T77	Qualifier 1196 1212	gastrointestinal
T78	Qualifier 1217 1224	biliary
T79	Condition 1225 1233	disorder
*	OR T78 T77 T76 T75
T80	Scope 1180 1224	Renal, hepatic, gastrointestinal, or biliary
R39	Has_scope Arg1:T79 Arg2:T80	
T81	Condition 1245 1262	impair absorption
T82	Condition 1245 1251;1264 1274	impair metabolism
T83	Condition 1245 1251;1278 1287	impair excretion
T84	Drug 1291 1321	orally administered medication
T85	Scope 1245 1287	impair absorption, metabolism or excretion
R40	AND Arg1:T85 Arg2:T84	
R41	Has_scope Arg1:T79 Arg2:T85	
T86	Temporal 1323 1333	Concurrent
T87	Condition 1334 1350	terminal illness
T88	Condition 1360 1374	severe disease
T89	Qualifier 1354 1359	other
R42	Has_qualifier Arg1:T88 Arg2:T89	
T90	Qualifier 1382 1388	active
T91	Condition 1389 1397	neoplasm
R43	Has_qualifier Arg1:T91 Arg2:T90	
T92	Scope 1382 1397	active neoplasm
*	OR T87 T88 T95
R44	Subsumes Arg1:T88 Arg2:T92	
T94	Procedure 1420 1430	laboratory
T95	Condition 1408 1439	significant laboratory value(s)
T93	Non-representable 1440 1523	which, in the opinion of the investigator, could preclude participation or survival
T96	Measurement 1420 1430	laboratory
R45	multi Arg1:T95 Arg2:T94	
R46	multi Arg1:T94 Arg2:T96	
T97	Scope 1334 1439	terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s)
R47	Has_temporal Arg1:T97 Arg2:T86	
T98	Condition 1525 1544	Endocrine disorders
T99	Condition 1553 1574	primary aldosteronism
T100	Condition 1576 1592	pheochromocytoma
T101	Condition 1604 1618	hypothyroidism
T102	Condition 1594 1599;1608 1618	hyper thyroidism
*	OR T99 T100 T102 T101 T104
T103	Qualifier 1620 1637	insulin-dependent
T104	Condition 1638 1655	diabetes mellitus
R48	Has_qualifier Arg1:T104 Arg2:T103	
T105	Scope 1553 1655	primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus
R49	Subsumes Arg1:T98 Arg2:T105	
T106	Observation 1657 1670;1684 1696	Unwillingness to cooperate
T107	Observation 1674 1696	inability to cooperate
*	OR T107 T106 T108 T110 T111 T109
T108	Observation 1657 1670;1701 1716;1730 1745	Unwillingness for the parents to give consent
T109	Observation 1674 1683;1701 1716;1730 1745	inability for the parents to give consent
T110	Observation 1657 1670;1701 1708;1720 1745	Unwillingness for the guardians to give consent
T111	Observation 1674 1683;1701 1708;1720 1745	inability for the guardians to give consent
T112	Condition 1856 1865	Pregnancy
T113	Mood 1869 1877	possible
T114	Condition 1878 1887	pregnancy
R50	Has_mood Arg1:T114 Arg2:T113	
*	OR T112 T114 T120 T131
T115	Temporal 1888 1912	at time of randomization
R51	Has_temporal Arg1:T114 Arg2:T115	
T116	Reference_point 1891 1912	time of randomization
R52	Has_index Arg1:T115 Arg2:T116	
T117	Person 1917 1923	female
T118	Observation 1927 1950	child bearing potential
T119	Observation 1959 1968	lactating
T120	Scope 1917 1968	female of child bearing potential who are lactating
T121	Observation 1973 1988	sexually active
T122	Negation 1993 1996	not
T123	Qualifier 2004 2012	adequate
T124	Observation 2013 2038	contraceptive precautions
R53	Has_qualifier Arg1:T124 Arg2:T123	
R54	Has_negation Arg1:T124 Arg2:T122	
T125	Device 2046 2065	intrauterine device
T126	Drug 2069 2088	oral contraceptives
T127	Temporal 2089 2131	for 3 months prior to entry into the study
T128	Reference_point 2111 2131	entry into the study
R55	Has_index Arg1:T127 Arg2:T128	
*	OR T126 T125
R56	Has_temporal Arg1:T126 Arg2:T127	
T129	Scope 2046 2131	intrauterine device or oral contraceptives for 3 months prior to entry into the study
T130	Scope 1993 2038	not taking adequate contraceptive precautions
R57	Subsumes Arg1:T130 Arg2:T129	
T131	Scope 1973 2132	sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)
T132	Drug 2144 2164	investigational drug
T133	Temporal 2165 2196	within 30 days of randomization
T134	Reference_point 2183 2196	randomization
R58	Has_index Arg1:T133 Arg2:T134	
T135	Temporal 2201 2248	within 5 half-lives of the investigational drug
T136	Drug 2228 2248	investigational drug
R60	multi Arg1:T135 Arg2:T136	
*	OR T133 T135
T137	Scope 2165 2248	within 30 days of randomization, or within 5 half-lives of the investigational drug
R59	Has_scope Arg1:T132 Arg2:T137	
T138	Observation 2281 2288	History
T139	Condition 2292 2308	drug sensitivity
T140	Condition 2312 2329	allergic reaction
T141	Drug 2333 2347	alpha-blockers
T142	Drug 2351 2364	beta-blockers
*	OR T141 T142
T143	Scope 2333 2364	alpha-blockers or beta-blockers
*	OR T139 T140
T144	Scope 2292 2329	drug sensitivity or allergic reaction
R61	Has_scope Arg1:T144 Arg2:T143	
R62	Has_temporal Arg1:T144 Arg2:T138	
T146	Temporal 2406 2439	within two weeks of randomization
T145	Drug 2441 2455	MAO inhibitors
T147	Drug 2457 2481	Calcium channel blockers
T148	Drug 2483 2497	alpha blockers
T149	Drug 2499 2512	beta blockers
T150	Drug 2514 2526	disopyramide
T151	Drug 2528 2538	flecainide
T152	Drug 2540 2549	encainide
T153	Drug 2551 2561	moricizine
T154	Drug 2563 2574	propafenone
T155	Drug 2576 2583	sotalol
T156	Drug 2588 2612	beta adrenergic agonists
*	OR T156 T155 T154 T153 T152 T151 T150 T149 T148 T147 T145
T157	Scope 2441 2612	MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists
R63	Has_temporal Arg1:T157 Arg2:T146	
T158	Procedure 2614 2632	Hospital admission
T159	Condition 2637 2663	protein losing enteropathy
T160	Condition 2667 2685	plastic bronchitis
T161	Temporal 2686 2718	within 3 months of randomization
*	OR T159 T160
T162	Scope 2637 2685	protein losing enteropathy or plastic bronchitis
R64	Has_scope Arg1:T158 Arg2:T162	
R65	Has_temporal Arg1:T158 Arg2:T161	
T163	Reference_point 2705 2718	randomization
R66	Has_index Arg1:T161 Arg2:T163	
T164	Qualifier 2720 2726	Active
T165	Qualifier 2734 2741	chronic
T166	Condition 2742 2768	protein losing enteropathy
T167	Condition 2772 2790	plastic bronchitis
T168	Drug 2795 2813	inhaled medication
R68	AND Arg1:T167 Arg2:T168	
*	OR T164 T165
*	OR T166 T167
T169	Scope 2742 2848	protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis)
T170	Scope 2720 2741	Active and/or chronic
R67	Has_scope Arg1:T169 Arg2:T170	
T171	Condition 2851 2866	Hypoalbuminemia
T172	Measurement 2878 2891	serum albumin
T173	Value 2892 2900	<2.0g/dL
R69	Has_value Arg1:T172 Arg2:T173	
R70	Subsumes Arg1:T171 Arg2:T172	
T174	Condition 2902 2919	Renal dysfunction
T175	Measurement 2931 2947	serum creatinine
T176	Value 2948 2957	>2.0mg/dL
R71	AND Arg1:T174 Arg2:T175	
R72	Has_value Arg1:T175 Arg2:T176	
T177	Condition 2959 2978	Hepatic dysfunction
T178	Measurement 2990 2999	serum AST
T179	Measurement 2990 2995;3007 3010	serum ALT
*	OR T178 T179
T180	Value 3010 3041	> 3 times upper limit of normal
T181	Scope 2990 3010	serum AST and/or ALT
R73	Has_value Arg1:T181 Arg2:T180	
T182	Value 3043 3065	approximately 120 IU/L
T183	Non-representable 3075 3101	will vary depending on age
R74	Subsumes Arg1:T180 Arg2:T182	
T184	Scope 2990 3102	serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age)
R75	Subsumes Arg1:T177 Arg2:T184	
T185	Qualifier 3105 3116	Significant
T186	Condition 3117 3123	anemia
T187	Condition 3127 3139	polycythemia
T188	Measurement 3151 3161	hemoglobin
T189	Value 3162 3170	>18gm/dL
T190	Measurement 3174 3184	hemoglobin
T191	Value 3185 3192	<7gm/dL
R77	Has_value Arg1:T190 Arg2:T191	
R78	Has_value Arg1:T188 Arg2:T189	
*	OR T188 T190
T192	Scope 3151 3192	hemoglobin >18gm/dL or hemoglobin <7gm/dL
*	OR T187 T186
T193	Scope 3105 3139	Significant anemia or polycythemia
R76	Subsumes Arg1:T193 Arg2:T192	
T194	Scope 3117 3139	anemia or polycythemia
R79	Has_qualifier Arg1:T194 Arg2:T185	
T195	Value 3194 3211	Severely elevated
T196	Measurement 3212 3221	serum BNP
R80	Has_value Arg1:T196 Arg2:T195	
T197	Measurement 3233 3236	BNP
T198	Value 3236 3245	>300pg/ml
R81	Has_value Arg1:T197 Arg2:T198	
T199	Scope 3194 3221	Severely elevated serum BNP
T200	Scope 3233 3245	BNP>300pg/ml
R82	Subsumes Arg1:T199 Arg2:T200	
